share_log

Individual Investors Own 42% of China Meheco Group Co., Ltd. (SHSE:600056) Shares but Private Companies Control 53% of the Company

Individual Investors Own 42% of China Meheco Group Co., Ltd. (SHSE:600056) Shares but Private Companies Control 53% of the Company

個人投資者擁有中國醫藥集團股份有限公司(SHSE:600056)42%的股份,但私營企業控制公司的53%。
Simply Wall St ·  06/20 19:58

Key Insights

主要見解

  • The considerable ownership by private companies in China Meheco Group indicates that they collectively have a greater say in management and business strategy
  • The top 3 shareholders own 53% of the company
  • Past performance of a company along with ownership data serve to give a strong idea about prospects for a business
  • 私營企業在中國醫藥集團中擁有大量所有權,這表明它們在管理和業務策略方面有更大的話語權。
  • 前三大股東擁有該公司53%的股份。
  • 公司過去的業績以及所有權數據,有助於形成對業務前景的強烈想法。

To get a sense of who is truly in control of China Meheco Group Co., Ltd. (SHSE:600056), it is important to understand the ownership structure of the business. We can see that private companies own the lion's share in the company with 53% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

要了解中國醫藥集團股份有限公司(SHSE:600056)的真正控制者,了解企業的所有權結構非常重要。我們可以看到,私營企業擁有該公司53%的所有權。也就是說,如果股票上漲,該集團將獲得最大的利益(或者如果出現低迷,將失去最多的利益)。

And individual investors on the other hand have a 42% ownership in the company.

另一方面,個人投資者擁有該公司42%的所有權。

Let's take a closer look to see what the different types of shareholders can tell us about China Meheco Group.

讓我們更詳細地了解一下不同類型的股東對中國醫藥集團的意義。

ownership-breakdown
SHSE:600056 Ownership Breakdown June 20th 2024
SHSE:600056的所有權結構拆分(截至2024年6月20日)

What Does The Institutional Ownership Tell Us About China Meheco Group?

機構所有權告訴我們什麼關於中國醫藥集團?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

機構投資者通常將自己的回報與常見的指數回報進行比較。因此,他們通常會考慮購買包括在相關基準指數中的較大公司。

China Meheco Group already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of China Meheco Group, (below). Of course, keep in mind that there are other factors to consider, too.

中國醫藥集團已經有機構在股份註冊表上。確實,他們擁有該公司的可觀份額。這表明專業投資者中有一定的信譽。但是我們不能僅僅依靠這個事實,因爲機構有時會犯錯,就像每個人都會犯錯一樣。如果兩個大型機構投資者同時試圖出售某隻股票,股價大幅下跌並不罕見。因此,檢查中國醫藥集團的過去收益軌跡(如下所示)是值得的。當然,也要記住考慮其他因素。

earnings-and-revenue-growth
SHSE:600056 Earnings and Revenue Growth June 20th 2024
SHSE:600056營收與利潤增長(截至2024年6月20日)

Hedge funds don't have many shares in China Meheco Group. The company's largest shareholder is China General Technology (Group) Holding Co.,Ltd., with ownership of 33%. For context, the second largest shareholder holds about 10% of the shares outstanding, followed by an ownership of 9.4% by the third-largest shareholder.

對於中國醫藥集團,對沖基金持股不多。該公司最大的股東是中國航天科技集團控股有限公司,持股33%。爲了更好地了解情況,其次大的股東持有約10%的流通股,第三大股東持股9.4%。

To make our study more interesting, we found that the top 3 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.

總的來說,包括散戶投資者在內,公衆擁有公司的14%的股份,因此不能輕易忽視。儘管這種所有權的規模可能不足以在他們的利益方面影響政策決策,但他們仍然可以對公司政策產生集體影響。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar.

普通公衆持有北方銅業的23%股份。雖然這個群體不能決定公司的命運,但它肯定會對公司運營方式產生真正的影響。

Insider Ownership Of China Meheco Group

中國醫藥集團內部持股情況

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

在不同國家,內部人員的定義可能會略有不同,但董事會成員始終是內部人員。管理層最終向董事會負責。然而,如果管理人員是創始人或CEO,那麼成爲執行董事會成員也是很常見的。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常認爲內部人士持股是一件好事。但是,在某些情況下,它會使其他股東更難以對董事會的決定進行問責。

We note our data does not show any board members holding shares, personally. Given we are not picking up on insider ownership, we may have missing data. Therefore, it would be interesting to assess the CEO compensation and tenure, here.

我們注意到我們的數據不顯示任何董事會成員持有股份。考慮到我們沒有掌握內部持股情況,我們可能有缺失的數據。因此,有趣的是評估首席執行官的薪酬和任期。

General Public Ownership

一般大衆所有權

The general public-- including retail investors -- own 42% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

普通公衆,包括零售投資者,擁有42%的股份,因此不能被輕易忽視。雖然這樣的持股規模可能不足以在其利益方面左右政策決策,但他們仍然可以對公司政策產生集體影響。

Private Company Ownership

私有公司的所有權

It seems that Private Companies own 53%, of the China Meheco Group stock. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

看起來私營企業擁有中國醫藥集團股票的53%。深入了解這一點可能是值得的。如果類似內部人士的相關方對其中一傢俬營企業有利益,那麼這應在年度報告中披露。私營企業也可能對公司有戰略利益。

Next Steps:

下一步:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Like risks, for instance. Every company has them, and we've spotted 3 warning signs for China Meheco Group (of which 1 is a bit concerning!) you should know about.

我發現看一個公司的實際控制者非常有趣。但是要真正獲得洞察力,我們還需要考慮其他信息。例如,風險。每家公司都有風險,我們已經發現了中國醫藥集團的三個警告信號(其中一個有點令人擔憂!)你應該了解。

Of course this may not be the best stock to buy. Therefore, you may wish to see our free collection of interesting prospects boasting favorable financials.

當然,這也可能不是最好的股票交易。因此,您可能想看看我們免費的潛力股票收藏,這些股票具有有利的財務狀況。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論